Novavax presents strategic update at J.P. Morgan; 2025 results pending

NOVAVAX INC

Preliminary financial results for year ended Dec 31, 2025 are being finalized and subject to change.
No specific financial metrics disclosed; presentation focuses on strategic and business updates.
Investor presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
Company cautions that actual results may differ materially from preliminary data.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.